Compare Eli Lilly And Co (LLY) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Xpeng Inc - ADR — how do they compare? Eli Lilly And Co trades at $1,178.99 (market cap $1.04T), while Xpeng Inc - ADR trades at $9.9 (market cap $9.16B). The key difference: Eli Lilly And Co is far larger — about 113.5× Xpeng Inc - ADR's market cap, and Eli Lilly And Co pays a 0.59% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Xpeng Inc - ADR for 80 Days on average.
| LLY | XPEV | |
|---|---|---|
Market Cap | $1.04T | $9.16B |
Volume | 3,064,878 | 5,030,325 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.28K | $28.07 |
52-Week Low | $799.57 | $9.25 |
Typical Hold Time | 93 Days | 80 Days |
Enterprise Value | $1.09T | $11.09B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
XPeng (XPEV) trades at $9.92, up 3.55% today, but remains in a bearish technical trend. The company shows mixed fundamentals with strong revenue growth to $76.72B in 2025 but persistent net losses. Recent Q2 2026 earnings missed expectations, though vehicle deliveries surged 65% quarter-over-quarter. Analyst consensus remains bullish with a $17.55 price target, representing 77% upside potential from current levels.
XPeng presents a high-risk, high-reward opportunity with significant growth potential in EVs and robotics, but profitability challenges and competitive pressures create substantial risk. The stock's current valuation at 0.81 P/S appears attractive if the company can achieve sustainable profitability, but investors face execution risk amid China's competitive EV market and global expansion challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
